Pharmacokinetic studies of riluzole show a large inter-individual variability of the drug's clearance and serum concentrations. Optimizing the individual dosage of riluzole may have the potential to improve the effect of riluzole treatment on survival of patients with amyotrophic lateral sclerosis (ALS). Limited data are available on the in vivo metabolic elimination of riluzole. From in vitro experiments, CYP1A2 seems to be mainly involved in riluzole clearance. However, in vitro studies suggest that formation of riluzole-glucuronide plays a role and may determine the drug's pharmacokinetic variability in patients to some extent. In the current study the formation of riluzole-glucuronide was examined in amyotrophic lateral sclerosis (ALS) patients. It also aimed at relating glucuronidation of riluzole to differential UGT1A1*28 genotypes. The formation of riluzole-glucuronide was confirmed in serum from a group of 14 ALS patients taking riluzole. Riluzole-glucuronide concentrations were positively associated with those of riluzole. In a separate group of 131 ALS patients taking riluzole, the UGT1A1*28 genotype was not associated with trough or peak serum concentrations of riluzole. This study provides evidence that the in vivo metabolic elimination of riluzole in ALS patients involves glucuronidation. The results do not indicate that glucuronidation of riluzole highly contributes to the drug's inter-individual pharmacokinetic variability.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/bdd.594 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hypothalamic atrophy in primary lateral sclerosis, assessed by convolutional neural network-based automatic segmentation.
Sci Rep
January 2025
Dept. of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
Primary lateral sclerosis (PLS) is a motor neuron disease (MND) which mainly affects upper motor neurons. Within the MND spectrum, PLS is much more slowly progressive than amyotrophic laterals sclerosis (ALS). `Classical` ALS is characterized by catabolism and abnormal energy metabolism preceding onset of motor symptoms, and previous studies indicated that the disease progression of ALS involves hypothalamic atrophy.
View Article and Find Full Text PDFRiluzole is associated with reduced risk of heart failure.
Eur J Neurol
January 2025
Department of Pharmacotherapy, University of Utah Health, Salt Lake City, Utah, USA.
Background: Reduction of intracellular Na accumulation through late Na current inhibition has been recognized as a target for cardiac Ca handling which underlies myocardial contractility and relaxation in heart failure (HF). Riluzole, an Na channel blocker with enhancement of Ca-activated K channel function, used for management of amyotrophic lateral sclerosis (ALS), is effective in suppressing Ca leak and therefore may improve cardiac function.
Objectives: The study aim was to investigate whether riluzole lowers HF incidence.
Emergency medical services level of training is associated with mortality in trauma patients: A combined prehospital and in hospital database analysis.
J Trauma Acute Care Surg
January 2025
From the Department of Surgery (J.H., K.S., G.S.C., C.T., L.R., G.B.); School of Public Health (A.B., O.H., A.S., S.M.); Hennepin Healthcare (S.K.); Department of Emergency Medicine (S.K., M.A.P.); and Hennepin Healthcare, Department of Emergency Medicine (M.A.P.), Minneapolis, Minnesota.
Background: There is conflicting evidence regarding emergency medical service (EMS) provider level of training and outcomes in trauma. We hypothesized that advanced life support (ALS) provider transport is associated with lower mortality compared with basic life support transport.
Methods: We performed secondary analysis of a combined prehospital and in-hospital database of trauma patients utilizing ESO electronic medical records from 2018 to 2022.
Biomarkers.
Alzheimers Dement
December 2024
Xiangya Hospital, Central South University, Changsha, Hunan, China.
Background: Frontotemporal dementia (FTD) exhibits clinical phenotypic and genetic heterogeneity. However, reports on the clinical phenotypic characteristics and the frequency of genetic mutations in large-sample Chinese populations with FTD are lacking. Furthermore, the FTD diagnostic performance of plasma neurodegenerative biomarkers remains unclear.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
UK Dementia Research Institute at University College London, London, United Kingdom; Dementia Research Centre at University College London, London, United Kingdom.
Transactive response DNA-binding protein 43 (TDP-43) has emerged as a pivotal player in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and the recently described limbic-predominant age-related TDP-43 encephalopathy (LATE). Detecting TDP-43 pathology in a minimally invasive manner is crucial for early diagnosis, monitoring disease progression and the assessment of therapeutic interventions. This talk explores recent advancements in the discovery and validation of novel biofluid measures aimed at detecting and characterising TDP-43 pathology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!